Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).

Véronique Hofman,Jonathan Benzaquen,Simon Heeke,Sandra Lassalle,Michel Poudenx,Elodie Long,Elisabeth Lantéri,Olivier Bordone,Virginie Lespinet,Virginie Tanga,Christelle Bonnetaud, Yvonne Bille,Marius Ilié,Charles Marquette,Fabrice Barlesi,Jacques Boutros,Paul Hofman

Lung Cancer（2020）

引用 14|浏览59

暂无评分

摘要

•Assessment of the BRAF status is mandatory in late stage NSCLC.•BRAFV600 mutated NSCLC are treated using a targeted therapy.•BRAFV600 IHC is an alternative tool of BRAFV600 molecular biology assays.•BRAF IHC can be used as a reflex testing in daily practice.

查看译文

关键词

BRAF,Non-small cell lung cancer,Immunohistochemistry,Molecular biology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要